866-997-4948(US-Canada Toll Free)

Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2019

Published By :

Current Partnering

Published Date : Sep 2019

Category :

Pharmaceutical

No. of Pages : 900 Pages

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2019 report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies
Executive Summary

Chapter 1 Introduction

Chapter 2 Why do companies partner preclinical stage compounds?

2.1. Introduction
2.2. The role of preclinical stage partnering
2.2.1. In-licensing at preclinical stage
2.2.2. Out-licensing at preclinical stage
2.3. Difference between discovery, preclinical and clinical stage deals
2.4. Reasons for entering into preclinical stage partnering deals
2.4.1. Licensors reasons for entering preclinical stage deals
2.4.2. Licensees reasons for entering preclinical stage deals
2.5. The future of preclinical stage partnering deals

Chapter 3 Preclinical stage deal strategies and structure

3.1. Introduction
3.2. At what stage do companies partner?
3.2.1. Partnering early in pharmaceutical / biotech
3.2.1.1. Discovery and preclinical stage partnering case studies
3.2.1.1.a. Case study: LEO Pharma - 4SC
3.2.1.1.b. Case study: Heptares Therapeutics - Cubist
3.2.1.1.c. Case study: Incyte Agenus Bio
3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec
3.2.2. Partnering later in pharmaceutical/biotech
3.2.2.1. Clinical stage partnering case studies
3.2.2.1.a. Case study: Servier GeNeuro
3.2.2.1.b. Case study: Teva Xenon Pharmaceuticals
3.2.2.1.c. Case study: AstraZeneca - Ardelyx
3.2.2.1.d. Case study: Baxter Onconova Therapeutics
3.3. Early and later stage partnering a risk/cost comparison
3.4. What do companies spend on preclinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.6.1. Example pure preclinical stage licensing agreements
3.6.1.a. Case study : Merck and Co. Tesaro
3.6.1.b. Case study : Marina Biotech Mirna Therapeutics
3.7. Multicomponent preclinical stage partnering agreements
3.7.1. Example multicomponent preclinical stage clauses
3.7.1.a. Case study: Eleven Biotherapeutics ThromboGenics
3.7.1.b. Case study: Pfizer InSite Vision

Chapter 4 Preclinical stage partnering payment strategies

4.1. Introduction
4.2. Preclinical stage payment strategies
4.3. Payment options
4.3.1. Headline values
4.3.2. Upfront payments
4.3.2.1. Conditionality of upfront payments
4.3.3. Loans
4.3.4. Convertible loans
4.3.5. Equity
4.3.6. R&D funding
4.3.7. Licensing fees
4.3.8. Milestone payments
4.3.9. Royalty payments
4.3.9.1. Issues affecting royalty rates
4.3.9.2. Royalties on combination products
4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech
4.3.9.3. Guaranteed minimum/maximum annual payments
4.3.9.4. Royalty stacking
4.3.9.5. Royalties and supply/purchase contracts
4.3.10. Quids
4.3.11. Option payments

Chapter 5 Trends in preclinical stage deal making

5.1. Introduction
5.2. Preclinical stage partnering over the years
5.2.1. Attributes of preclinical deals
5.3. Preclinical stage partnering by deal type
5.4. Preclinical stage partnering by disease type
5.5. Partnering by preclinical stage technology type
5.6. Preclinical stage partnering by most active company since 2014

Chapter 6 Payment terms for preclinical stage partnering

6.1. Introduction
6.2. Guidelines for preclinical stage payment terms
6.2.1. Upfront payments
6.2.2. Milestone payments
6.2.3. Royalty payments
6.3. Preclinical stage payment terms deal data analysis
6.3.1. Public data
6.3.2. Survey data
6.4. Payment terms analysis
6.4.1. Preclinical stage headline values
6.4.2. Preclinical stage deal upfront payments
6.4.3. Preclinical stage deal milestone payments
6.4.4. Preclinical stage royalty rates

Chapter 7 Leading preclinical stage deals

7.1. Introduction
7.2. Top preclinical stage deals by value

Chapter 8 Top 25 most active preclinical stage dealmakers

8.1. Introduction
8.2. Top 25 most active preclinical stage dealmakers

Chapter 9 Preclinical stage partnering contracts directory

9.1. Introduction
9.2. Preclinical stage deals with contracts 2014 to 2019

Chapter 10 Preclinical stage deal making by development stage

10.1. Introduction
10.2. Deals by preclinical stage

Appendices

Appendix 1 Preclinical stage dealmaking by companies A-Z
Appendix 2 Preclinical stage dealmaking by industry sector
Appendix 3 Preclinical stage dealmaking by stage of development
Appendix 4 Preclinical stage dealmaking by therapy area
Appendix 5 Preclinical stage dealmaking by technology type

About Wildwood Ventures

Current Partnering
Current Agreements
Recent titles from Current Partnering

Table of figures

Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
Figure 2: Agreements signed by phase of development (2014- 2019), % of all deals
Figure 3: Components of the pure licensing deal structure
Figure 4: Payment options for preclinical stage partnering deals
Figure 5: Issues affecting royalty rates
Figure 6: Preclinical stage partnering frequency since 2014
Figure 7: Preclinical stage partnering by deal type since 2014
Figure 8: Preclinical stage partnering by disease type since 2014
Figure 9: Preclinical stage partnering by technology type since 2014
Figure 10: Top 25 most active preclinical stage dealmakers since 2014
Figure 11: Review of upfront payments for preclinical stage deals
Figure 12: Review of milestone payments for preclinical stage deals
Figure 13: Review of royalty payments for preclinical stage deals
Figure 14: Preclinical stage deals with a headline value
Figure 15: Preclinical stage deals with an upfront value
Figure 16: Preclinical stage deals with a milestone value
Figure 17: Preclinical stage deals with a royalty rate value
Figure 18: Top preclinical stage deals by value since 2014
Figure 19: Most active preclinical stage dealmakers since 2014

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *